Stay updated on Exemestane in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Exemestane in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Exemestane in NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The record now displays details of the completed Phase II exemestane study for post-menopausal women with advanced NSCLC, including eligibility criteria, locations, study outcomes, and posted results.
    Difference
    50%
    Check dated 2026-11-08T23:15:31.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T23:18:42.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH website terminology transition from “Artificial Intelligence” to “Super Intelligence.” The study record area continues to show a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-10-25T22:37:13.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:49:41.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer’s site revision marker changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T23:09:16.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The study record page continues to display a 403 Forbidden error instead of study information.
    Difference
    0.2%
    Check dated 2026-10-04T22:24:39.000Z thumbnail image

Stay in the know with updates to Exemestane in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Exemestane in NSCLC Clinical Trial page.